Mitigating Ocular Surface Disease in Patients With Glaucoma - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Mitigating Ocular Surface Disease in Patients With Glaucoma

Learn about the critical need to evaluate glaucoma patients for ocular surface disease and the proactive measures to ensure optimal visual outcomes.

  • By

  • Zarmeena Vendal, MD

  • March 1, 2025

  • 8 min

Share

Original Source(s)

Mitigating Ocular Surface Disease in Patients With Glaucoma

  • by Zarmeena Vendal, MD

  • March 1, 2025

Related Content

Artificial intelligence in ophthalmology: an invisible environmental footprint

Mapping the FLIGHT Path

How incision-free intervention could expand glaucoma treatment options

Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?

A large US cohort study found systemic alpha-2 agonist use was associated with a lower hazard of glaucoma-related diagnoses vs. beta-blockers.